• BMN 673 (Talazoparib): Precision Synthetic Lethality and ...

  2025-09-29

  Discover how BMN 673 (Talazoparib), a potent PARP1/2 inhibitor, exploits synthetic lethality in homologous recombination deficient cancers. This in-depth analysis unveils novel mechanistic insights and translational applications, distinguishing itself from existing reviews.

• BMN 673 (Talazoparib): Redefining Synthetic Lethality in ..

  2025-09-28

  Explore how BMN 673 (Talazoparib), a potent PARP1/2 inhibitor, uniquely exploits DNA repair deficiencies through advanced PARP-DNA complex trapping. This in-depth analysis unveils emerging mechanistic insights and translational strategies distinct from previous reviews.

• BMN 673 (Talazoparib): Mechanistic Insights and Rational ...

  2025-09-27

  Explore the unparalleled potency and selectivity of BMN 673 (Talazoparib) as a potent PARP1/2 inhibitor for homologous recombination deficient cancer treatment. This article delivers novel mechanistic perspectives and translational strategies, expanding beyond current reviews.

• BMN 673 (Talazoparib): Precision Targeting of DNA Repair ...

  2025-09-26

  Explore how BMN 673 (Talazoparib), a potent PARP1/2 inhibitor, leverages advanced insights into PARP-DNA complex trapping and homologous recombination to revolutionize selective cancer research. This article provides a mechanistic deep dive and strategic guidance for PI3K pathway modulation and DNA repair deficiency targeting.

• Pioglitazone and PPARγ: Unlocking Immune-Metabolic Crosst...

  2025-09-25

  Explore how Pioglitazone, a PPARγ agonist, uniquely modulates immune-metabolic pathways in research, advancing understanding of insulin resistance and inflammation. Discover novel insights into macrophage polarization and beta cell protection with this comprehensive analysis.

• Sildenafil Citrate: Advanced Proteoform-Targeted Strategi...

  2025-09-24

  Explore the scientific foundations and cutting-edge applications of Sildenafil Citrate as a selective cGMP-specific phosphodiesterase type 5 inhibitor for cardiovascular research. This article uniquely integrates proteoform-targeted drug discovery, native MS insights, and vascular signaling dynamics.

• (S)-Mephenytoin as a CYP2C19 Substrate: Advancing Human I...

  2025-09-23

  Explore the application of (S)-Mephenytoin as a mephenytoin 4-hydroxylase substrate in innovative human intestinal organoid models for pharmacokinetic research. This article examines technical considerations and scientific advancements in CYP2C19 substrate utilization for in vitro CYP enzyme assay development.

• The canonical binding sites to which or

  2025-04-16

  

  The canonical HotStart™ 2X Green qPCR Master Mix to which α2, α3, or α5 contribute are highly similar. Therefore, differences in ligand affinity will not be large even if a ligand makes optimal use of the small differences in the pockets. As a possible alternative approach to achieve separation of c

• br Materials and methods br Results br Discussion Because

  2025-04-15

  

  Materials and methods Results Discussion Because the Ser/Thr kinase domain of LRRK2 is homologous to that of other MLK family proteins belonging to the MAP3K superfamily, LRRK2 is suggested to be involved in MAPK signaling and activation of neuronal cell death by phosphorylating its downstr

• br Leptin Adiponectin a permissive imbalance Leptin

  2025-04-14

  

  Leptin/Adiponectin: a permissive imbalance Leptin, a satiety hormone, is encoded by the obesity (ob) gene. It essentially functions as an energy sensor which is involved in the regulation of body weight by sending signals to the Sulfo-NHS-Biotin to reduce appetite (Woods and D'Alessio, 2008). Ob

• br Introduction Rhamdia quelen jundi Silurifomes Heptapterid

  2025-04-14

  

  Introduction Rhamdia quelen (jundiá, Silurifomes, Heptapteridae) is a neotropical catfish widely distributed in Central and South America (Silfvergrip, 1996). This species shows high potential for the aquaculture industry, due to an elevated growth rate, good carcass yield, and easy reproduction

• Aprotinin br Conflicts of interest br Introduction Photodyna

  2025-04-11

  

  Conflicts of interest Introduction Photodynamic Therapy (PDT) is a technique used for the treatment of several malignant and non malignant diseases (Akimoto, 2016, Keyal, Bhatta, Wang, 2016, Morton, Szeimies, Sidoroff, Wennberg, Basset-Seguin, Calzavara-Pinton, Gilaberte, Hofbauer, Hunger, Kar

• br Acknowledgment This study was supported by Japan Society

  2025-04-11

  

  Acknowledgment This study was supported by Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (KAKENHI) [grant number 15K15031]. Introduction Glioma is the leading malignancy of astrocyte origin in the brain. The most aggressive, invasive, and destructive glioma

• Atherosclerosis is a chronic lipid metabolism disorder linke

  2025-04-11

  

  Atherosclerosis is a chronic lipid metabolism disorder linked with lipid accumulation within the arterial wall and subsequent formation of foam cells and vascular disease [96], [97]. The level of apelin is decreased in human atherosclerotic coronary arteries [4], and coronary collateral formation in

• br Conclusion We present here the first

  2025-04-10

  

  Conclusion We present here the first comprehensive analysis of B-Raf-induced transcriptional activation in insulinoma cells. The B-Raf-induced signaling cascade targets the c-Fos and the c-Jun genes. Both gene products are constituents of the AP-1 transcription factor. The phosphatases MKP-1 and

8326 records 33/556 page Previous Next First page 上5页 3132333435 下5页 Last page